Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”

Young Eun Chon; Dong Yun Kim; Hong Jae Chon; Do Young Kim

doi:10.3350/CMH.2024.0394

YUHSpace

BROWSE

Cited 0 times in

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”

Authors: Young Eun Chon ; Dong Yun Kim ; Hong Jae Chon ; Do Young Kim

Citation: CLINICAL AND MOLECULAR HEPATOLOGY, Vol.30(4) : 1005-1008, 2024-10

Journal Title: CLINICAL AND MOLECULAR HEPATOLOGY

ISSN: 2287-2728

Issue Date: 2024-10

Keywords: Atezolizumab and bevacizumab failure ; Hepatocellular carcinoma ; Immune check point inhibitor ; Salvage therapy

Files in This Item:: T992024707.pdf Download

DOI: 10.3350/CMH.2024.0394

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Kim, Do Young(김도영)

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/202325

사서에게 알리기

Show full item record

License

YUHSpace: Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”

YUHSpace

BROWSE

Browse

Links